Medication adherence and persistence among patients with non-small cell lung cancer receiving tyrosine kinase inhibitors and estimation of the economic burden associated with the unused medicines
Restricted accessResearch articleFirst published online October, 2022
Medication adherence and persistence among patients with non-small cell lung cancer receiving tyrosine kinase inhibitors and estimation of the economic burden associated with the unused medicines
Non–small cell lung cancer (NSCLC) is a leading cause of cancer deaths. Its treatment includes specific oral tyrosine kinases inhibitors (TKIs).
Objectives
To estimate adherence and persistence among patients receiving TKIs and to assess the economic burden of the unused medicines in Alsace (France).
Method
This retrospective study was carried out using the Insurance Healthcare database.
Main outcome measures
Adherence was calculated using medication possession ratio (MPR), persistence using estimated level of persistence with therapy (ELPT) and economic impact using prescription refill data.
Results
242 patients were receiving TKIs. The most common TKIs prescribed were erlotinib (75.6%, n = 183) and crizotinib (12.8%, n = 31). Total of 149 patients were included in the adherence analysis. Overall MPR was 0.98. 180 patients were included in the persistence analysis. Almost half of patients had stopped treatment at 60 days and only 38.3% (n = 69) were still persistent with the therapy at 120 days. The expenses related to unused TKIs amounted to €356,392 and were related majorly to treatment discontinuation followed by overlapping refills, patient deaths and dose- or drug-switching, respectively.
Conclusions
Our data indicated overall adherence medicines above the acceptable limit of 0.80 but also pointed out a significant decline in persistence over time. The resulting economic losses justify the need for physicians and pharmacists to closely monitor their patients to ensure continuity of treatment. To limit the cost associated with unused medicines, interventions such as app-based monitoring, dispensing TKIs per unit over shorter periods and not only on monthly intervals could be implemented.
EttingerDSWoodDEAisnerDL, et al.
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Comprehens Cancer Netw2017;
15: 504–535.
2.
SchottSSchneeweissAReinhardtJ, et al.
Acceptance of oral chemotherapy in breast cancer patients—a survey study. BMC Cancer2011;
11: 2020–2022.
3.
CheungWY.Difficult to swallow: issues affecting optimal adherence to oral anticancer agents.Am Soc Clin Oncol Educ Book2013;
33: 265–270.
4.
LiuGFranssenEFitchMI, et al.
Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol1997;
15: 110–115.
5.
CramerJAScheyerRDMattsonRH.Compliance declines between clinic visits. Arch Intern Med1990;
150: 1509–1510.
6.
GreerJAAmoyalNNisotelL, et al.
A systematic review of adherence to oral antineoplastic therapies. Oncologist2016;
21: 354–376.
7.
GiannettiVJKamalKM.Adherence with therapeutic regimens: behavioral and pharmacoeconomic perspectives. J Pharm Pract2016;
29: 138–143.
8.
BareschinoMASchettinoCTroianiT, et al.
Erlotinib in cancer treatment. Ann Oncol2007;
18: vi35–41.
9.
CramerJARoyABurrellA, et al.
Medication compliance and persistence: terminology and definitions. Value Health2008;
11: 44–47.
10.
AndradeSEKahlerKHFrechF, et al.
Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf2006;
15: 565–574.
11.
SikkaRXiaFAubertRE.Estimating medication persistency using administrative claims data. Am J Manag Care2005;
11: 449–457.
12.
SattlerELPLeeJSPerriM.Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature.Drugs Aging2013;
30: 383–399.
13.
AndersonAMHigginsMKOwnbyRL, et al.
Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence. AIDS Care2015;
27: 333–337.
14.
LoflandJJohnsonPInghamM, et al.
Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adher2017;
11: 947–958.
15.
SealBSAndersonSShermockKM.Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer. J Manag Care Specialty Pharm2016;
22: 227–235.
16.
BriesacherBAAndradeSEFouayziH, et al.
Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy2008;
28: 437–443.
17.
BarilletMPrevostVJolyF, et al.
Oral antineoplastic agents: how do we care about adherence?Br J Clin Pharmacol2015 ;
80: 1289–1302.
18.
PetersonAMNauDPCramerJA, et al.
A checklist for medication compliance and persistence studies using retrospective databases. Value Health2007;
10: 3–12.
RichardTIssaR, AEGourieuxB, et al.
Iatrogenic hypoglycemia–related hospital admissions identified through databases: economic burden and causes. Int J Clin Pharm2019;
41: 1159–1165.
22.
NeuzilletCGaujouxSWillietN, et al.
Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC. Digest Liver Dis2018;
50: 1257–1271.
23.
HammelPHuguetFvan LaethemJ-L, et al.
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA2016;
315: 1844.
24.
OsterbergLBlaschkeT.Adherence to medication. N Engl J Med2005;
353: 487–497.
25.
VermeireEHearnshawHVan RoyenP, et al.
Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther2001;
26: 331–342.
26.
JimmyBJoseJ.Patient medication adherence: measures in daily practice. Oman Med J2011;
26: 155–159.
27.
LamWYFrescoP.Medication adherence measures: an overview. BioMed Res Int2015;
2015: 1–12.
28.
AliEEChanSSLLeowJL, et al.
User acceptance of an app-based adherence intervention: Perspectives from patients taking oral anticancer medications. J Oncol Pharm Pract2019;
25: 390–397.
29.
AliEELeowJLChewL, et al.
Patients’ perception of app-based educational and behavioural interventions for enhancing oral anticancer medication adherence. J Canc Educ2018;
33: 1306–1313.
30.
TimmersLBoonsCCLMMoes-ten HoveJ, et al.
Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol2015;
141: 1481–1491.
31.
GebbiaVBellaviaMBannaGL, et al.
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non–small-cell lung cancer. Clin Lung Cancer2013;
14: 390–398.
32.
BronteGRolfoCGiovannettiE, et al.
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol2014;
89: 300–313.
33.
FrohnaPLuJEpplerS, et al.
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol2006;
46: 282–290.
34.
LiangWWuXFangW, et al.
Network Meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One2014;
9: e85245.
35.
BekkerCLMelisEJEgbertsACG, et al.
Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. Res Soc Admin Pharm2019;
15: 100–105.
36.
WestLMDiackLCordinaM, et al.
A systematic review of the literature on ‘medication wastage’: an exploration of causative factors and effect of interventions. Int J Clin Pharm2014;
36: 873–881.
37.
DuerdenMAveryTPayneR.Polypharmacy and medicines optimisation: making it safe and sound.
London:
King’s Fund, 2013.
38.
WolfMSDavisTCShrankW, et al.
To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns2007 ;
67: 293–300.
39.
MillarJMacKinnonWStruthersMV, et al.
A pilot study to investigate the use of installment dispensing as a method of reducing drug wastage owing to adverse drug reactions. Br J Gen Pract2003;
53: 550.
40.
KhandelwalNDuncanIAhmedT, et al.
Impact of clinical oral chemotherapy program on wastage and hospitalizations. J Oncol Pract2011;
7: e25s–e29s.
41.
GalligioniEPirasEMGalvagniM, et al.
Integrating mHealth in oncology: experience in the province of Trento. J Med Internet Res2015;
17: e114.
